NCT05164263 - Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

August 31, 2027

Conditions

Type II Diabetes MellitusEfficacy, SelfSafety Issues

Interventions

DRUG

Empagliflozin

Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg

Trial Locations (6)

Unknown

COMPLETED

Kabul University of Medical Sciences(KUMS), Kabul

RECRUITING

Agha Khan univeristy hospital, Nairobi

RECRUITING

Lagos University Teaching Hospital, Lagos

RECRUITING

Umar Diabetes Foundation, Islamabad

RECRUITING

National hospital Sri Lanka, Colombo

RECRUITING

NHK, Kandy